Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical Trial
The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries. The primary efficacy endpoint will assess improvement in symptoms for the entire population (nHCM and
Lexicon finished signing up more patients than expected for an important test of a heart medicine. When a company does well at recruiting for a big trial, it's a sign they have doctor and patient support, though we still need to wait for the actual results.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.